Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | MC5R | P33032 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052467 | 0.82 | TACR1 (0.40) | TACR1PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL31058670 | 0.81 | NR1H2 (0.38) | TACR1PARP1MC4RMC5R | |
| SCHEMBL28913738 | 0.81 | NR1H2 (0.42) | ALOX5APFEN1 | |
| SCHEMBL30775551 | 0.78 | ALOX5AP (0.36) | TACR1PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL5333905 | 0.78 | HTR2C (0.47) | PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL1769797 | 0.78 | TACR1 (0.43) | TACR1HTR2AHTR2CHTR2B | |
| SCHEMBL5119466 | 0.77 | PARP1 (0.38) | TACR1PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL30502301 | 0.77 | HTR2C (0.44) | TACR1PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL5827279 | 0.77 | HTR2C (0.43) | TACR1PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL13647340 | 0.76 | TACR1 (0.59) | TACR1PARP1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |